hgb 205 follow up results

Summary

After 2 years in HGB-205, patients with TDT (n=4) and SCD (n=3) had a median follow-up of 49.6 (40.5-60.6) and 28.5 (25.5-52.5) months, respectively. 1 The second study, HGB-205, treated 3 patients with sickle cell disease and 4 with β-thalassemia, with follow-up ranging from 20 months to more than 3 years. 2 Patients were then observed in long-term follow-up studies LTF-303 (NCT02633943) and LTF-307 (NCT04628585) for TDT and SCD, respectively. 3

According to

1 ashpublications.org 2 www.nejm.org 3 www.nature.com

Summaries from the best pages on the web

The proof of concept for LentiGlobin gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) was established in the recently completed HGB-205 study (NCT02151526). Herein, we…

Results from the Completed Hgb-205 Trial of Lentiglobin for β ...

ashpublications.org

Subjects with sickle-cell disease. Subjects treated with ex vivo gene therapy drug product for sickle cell disease in a bluebird bio-sponsored study who agree to participate in this long-term follow-up…

Long-term Follow-up of Subjects With Sickle Cell Disease Treated With ...

clinicaltrials.gov

Summary HGB-205 is a phase 1/2, open-label, single-arm, non-randomized interventional study of 2-year duration at a single center, followed by observation in long-term follow-up studies LTF-303 ( NCT02633943 ) and LTF-307 ( NCT04628585 ) for TDT and SCD, respectively.

Long-term outcomes of lentiviral gene therapy for the β ... - Nature

nature.com

HGB-205 is a phase 1/2, open-label, single-arm, non-randomized interventional study of 2-year duration at a single center, followed by observation in long-term follow-up studies LTF-303 ( NCT02633943) and LTF-307 (…

Long-term outcomes of lentiviral gene therapy for the β ...

nih.gov

Summary The second study, HGB-205, which was conducted at a single site in Paris, treated 3 patients with sickle cell disease 25 and 4 with β-thalassemia, with follow-up ranging from 20 months to more than 3 years

Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia

nejm.org

Introduction: β-globin gene transfer into hematopoietic stem cells (HSCs) has the potential to reduce or eliminate the symptoms of severe sickle cell disease (SCD) and reduce or eliminate transfusion requirements …

Update from the Hgb-205 Phase 1/2 Clinical Study of Lentiglobin Gene ...

ashpublications.org

A total of 23 patients were enrolled and received treatment, with a median follow - up of 29.5 months (range, 13.0 to 48.2). Transfusion independence occurred in 20 of 22 patients who…

Betibeglogene Autotemcel Gene Therapy for Non–β0

nejm.org

HGB - 205 is an ongoing, open-label, single-center Phase 1/2 study designed to evaluate the safety and efficacy of LentiGlobin drug product in the treatment of patients with TDT and severe SCD.…

bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug ...

bluebirdbio.com

Results and Follow - Up What do the test results mean? A hemoglobin test can show if your levels are too low, as with anemia, or too high. It can also show…

Hemoglobin Test: What It Is, Procedure & Results - Cleveland Clinic

clevelandclinic.org

Longterm Follow - up of Subjects With Transfusion-Dependent β-Thalassemia Treated With Ex Vivo Gene Therapy. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.…

Longterm Follow-up of Subjects With Transfusion-Dependent β-Thalassemia ...

clinicaltrials.gov